Recent evidence from animal models of diabetes and human diabetic subjects suggests that the reduced availability of neurotrophic factors may contribute to the pathogenesis of diabetic peripheral neuropathy (DPN). Of these proteins, nerve growth factor (NGF), brain-derived neurotrophic factor, neurotrophin (NT-3) and NT-4/5 appear to be important for the development and maintenance of peripheral neurons, but others, including insulin-like growth factors (IGFs), may also be involved. Studies with NGF, NT-3, IGF-I and IGF-II both in vitro and in animal models of neuropathies (including DPN) suggest that these factors ameliorate nerve degeneration. Recombinant human NGF is the first neurotrophic factor to enter clinical trials for DPN and is currently being tested in two phase III studies.

1.
Thomas PK, Tomlinson DR: Diabetic and hypoglycemic neuropathy; in Dyck PJ, Thomas PK, Griffin JW (eds): Peripheral Neuropathy, ed 3. Philadelphia, Saunders, 1993, pp 1219–1250.
2.
Guy RJ, Clark CA, Malcolm PN, Watkins PJ: Evaluation of thermal and vibration sensation in diabetic neuropathy. Diabetologia 1985;28:131–137.
3.
Young RJ, Zhou YQ, Rodriguez E, Prescott RJ, Ewing DJ, Clarke BF: Variable relationship between peripheral somatic and autonomic neuropathy in patients with different syndromes of diabetic polyneuropathy. Diabetes 1986;35:192–197.
4.
Brown MJ, Martin JR, Asbury AK: Painful diabetic neuropathy: A morphometric study. Arch Neurol 1976;33:164–171.
5.
Parkhouse N, Le Quesne PM: Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. N Engl J Med 1988;318:1306–1309.
6.
Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, Poduslo JF: Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988;319:542–548.
7.
Johnson PC, Doll SC, Cromey DW: Pathogenesis of diabetic neuropathy. Ann Neurol 1986;19:450–457.
8.
Cameron NE, Cotter MA: Neurovascular dysfunction in diabetic rats. Potential contribution of autooxidation and free radicals examined using transition metal chelating agents. J Clin Invest 1995;96:1159–1163.
9.
Sidenius P, Jakobsen J: Retrograde axonal transport. A possible role in the development of neuropathy. Diabetologia 1981;20:110–112.
10.
Apfel SC: What are neurotrophic factors? in Apfel SC (ed): Clinical Applications of Neurotrophic Factors. Philadelphia, Lippincott-Raven, 1994, pp 1–54.
11.
Kaplan DR, Martin-Zanca D, Parada LF: Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 1991;350:158–160.
12.
Klein R, Nanduri V, Jing SA: The trk B tyrosine protein kinase is a receptor for brain derived neurotrophic factor and neurotrophin-3. Cell 1991;66:395–403.
13.
Lamballe F, Klein R, Barbacid M: Trk C, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 1991;66:967–979.
14.
Anton ES, Weskamp G, Reichardt LF, Matthew WD: Nerve growth factor and its low affinity receptor promote Schwann cell migration. Proc Natl Acad Sci USA 1994;91:2795–2799.
15.
Herrmann JL, Menter DG, Hamada J, Marchetti D, Nakajima M, Nicolson GL: Mediation of NGF stimulated extracellular matrix invasion by the human melanoma low affinity p75 neurotrophin receptor: Melanoma p75 functions independently of trk A. Mol Biol Cell 1993;4:1205–1216.
16.
Dobrowsky RT, Werner MH, Castellino AM, Chao MV, Hannun YA: Activation of the sphingomyelin cycle through the low affinity neurotrophin receptor. Science 1994;265:1596–1599.
17.
Carter BD, Kaltschmidt C, Kaltschmidt B, Offenhauser N, Bohm-Matthaei R, Baeuele PA, Barde YA: Selective activation of NF-kB by nerve growth factor through the neurotrophin receptor p75. Science 1996;272:542–545.
18.
Hellweg R, Hartung HD: Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990;26:258–267.
19.
Jakobsen J, Brimijoin S, Sklau K, Sidenius P, Wells D: Retrograde axonal transport of transmitter enzymes, fucose labelled protein and nerve growth factor in streptozotocin diabetic rats. Diabetes 1981;30:797–803.
20.
Ordonez G, Fernandez A, Perez R, Sotelo J: Low contents of nerve growth factor in serum and submaxillary glands of diabetic mice. J Neurol Sci 1994;121:163–166.
21.
Brewster WJ, Fernyhough P, Diemel LT, Mohiaddin L, Tomlinson DR: Diabetic neuropathy, nerve growth factor and other neurotropic factors. Trends Neurosci 1994;17:321–325.
22.
Hellweg R, Wohrle M, Hartung H-D, Stracke H, Hock C, Federlin K: Diabetes mellitus-associated decrease in nerve growth factor levels is reversed by allogeneic pancreatic islet transplantation. Neurosci Lett 1991;125:1–4.
23.
Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi DV: The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 1996;2:703–707.
24.
Tomlinson DR, Fernyhough P, Diemel LT: Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factor. Diabetes 1997;46:S43–S49.
25.
Crosby SR, Tsigos C, Anderton CD, Gordon C, Young RJ, White A: Elevated plasma insulin- like growth factor binding protein I levels in type I (insulin-dependent) diabetic patients with peripheral neuropathy. Diabetologia 1992;35:868–872.
26.
Wuarin L, Guertin DM, Ishii DN: Early reduction in insulin-like growth factor gene expression in diabetic nerve. Exp Neurol 1994;130:106–114.
27.
Ishii DN: Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Rev 1994;20:47–67.
28.
Johnson EM Jr: Destruction of the sympathetic nervous system in neonatal rats and hamsters by vinblastine: Prevention by concomitant administration of nerve growth factor. Brain Res 1978;141:105–118.
29.
Peterson ER, Crain SM: Nerve growth factor attenuates neurotoxic effects of Taxol on spinal cord-ganglion explants from fetal mice. Science 1982;217:377–379.
30.
Hayakawa K, Sobue G, Itoh T, Mitsuma T: Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and Taxol on adult rat sympathetic explants in vitro. Life Sci 1994;55:519–525.
31.
Konings PNM, Makkink WK, van Delf AML, Ruigt GSF: Reversal by NGF of cytostatic drug reduction of neurite outgrowth in dorsal root ganglia in vitro. Brain Res 1994;640:195–204.
32.
Corvaja N, Di Luzio A, Biocca S, Cattaneo A, Calissano P: Morphological and ultrastructural changes in PC12 pheochromocytoma cells induced by a combined treatment with NGF and Taxol. Exp Cell Res 1982;142:385–395.
33.
Black MM, Aletta JM, Greene LA: Regulation of microtubule composition and stability during nerve growth factor promoted neurite outgrowth. J Cell Biol 1986;103:547–557.
34.
Drubin DG, Feinstein SC, Shooter EM, Kirschner MW: Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assembly-promoting factors. J Cell Biol 1985;101:1799–1807.
35.
Apfel SC, Lipton RB, Arezzo JC, Kessler JA: Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991;29:87–90.
36.
Gao WQ, Dybdal N, Shinsky N, Murnane A, Schmelzer C, Siegel M, Keller G, Hefti F, Phillips HS, Winslow JW: Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 1995;38:30–37.
37.
Helgren ME, Cliffer KD, Torrento K, Cavnor C, Curtis R, DiStefano PS, Wiegand SJ, Lindsay RM: Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy. J Neurosci 1997;17:372–382.
38.
Windebank AJ, Smith AG, Russell JW: The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 1994;44:488–494.
39.
Apfel SC, Arezzo JC, Lipson L, Kessler JA: Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992;31:76–80.
40.
Apfel SC, Wright DE, Wiideman AM, Dormia C, Snider WD, Kessler JA: Nerve growth factor regulates the expression of brain derived neurotrophic factor mRNA in the peripheral nervous system. Mol Cell Neurosci 1996;7:134–142.
41.
Michael GJ, Averill S, Nitkunan A, Rattray M, Bennett DL, Yan Q, Priestly JV: Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in Trk A-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J Neurosci 1997;17:8476–8490.
42.
Contreras PC, Vaught JL, Gruner JA, Brosnan C, Steffler C, Arezzo JC, Lewis ME, Kessler JA, Apfel SC: Insulin-like growth factor-I prevents development of vincristine neuropathy in mice. Brain Res 1997;774:20–26.
43.
Contreras C, Steffler C, Gruner JA, Yee A, Roberts-Lewis J, Vaught JL: Recombinant insulin like growth factor-I (rhIGF-I) prevents cisplatin induced neuropathy (abstract 20). Soc Neurosci 1994, p 1096.
44.
Bennett GJ, Xie Y-K: A peripheral mononeuropathy in the rat produces disorders of pain sensation like those seen in man. Pain 1988;33:87–107.
45.
Ren K, Thomas DA, Dubner R: Nerve growth factor alleviates a painful peripheral neuropathy in rats. Brain Res 1995;699:286–292.
46.
Thomas PK: Diabetic neuropathy: Models, mechanisms and mayhem. Can J Neurol Sci 1992;19:1–7.
47.
Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA: Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994;634:7–12.
48.
Fernyhough P, Diemel LT, Hardy J, Brewster WJ, Mohiuddin L, Tomlinson DR: Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur J Neurosci 1995;7:1107–1110.
49.
Elias KA, Cronin MJ, Stewart TA, Carlsen RC: Peripheral neuropathy in transgenic diabetic mice: Restoration of C-fiber function with human recombinant nerve growth factor. Diabetes 1998;47:1637–1642.
50.
Zhuang HX, Snyder CK, Pu SF, Ishii DN: Insulin-like growth factors reverse or arrest diabetic neuropathy: Effects on hyperalgesia and impaired nerve regeneration in rats. Exp Neurol 1996;140:198–205.
51.
Ishii DN, Lupien SB: Insulin like growth factors protect against diabetic neuropathy: Effects on sensory nerve regeneration in rats. J Neurosci Res 1995;40:138–144.
52.
Engele J, Schubert D, Bohn MC: Conditioned media derived from glial cell lines promote the survival and differentiation of dopaminergic neurons in vitro: Role of mesencephalic glia. J Neurosci Res 1991;30:359–371.
53.
Lin L-F, Doherty DH, Lile JD, Bektesh S, Collins F: GDNF: A glial cell line derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130–1132.
54.
Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, Moffet B, Vandlen RA, Koliatsos VE, Rosenthal A: GDNF: A potent survival factor for motorneurons present in peripheral nerve and muscle. Science 1994;266:1062–1064.
55.
Buj-Bello A, Buchman VL, Horton A, Rosenthal A, Davies AM: GDNF is an age-specific survival factor for sensory and autonomic neurons. Neuron 1995;15:821–828.
56.
Lin L-F, Doherty DH, Lile JD, Bektesh S, Collins F: GDNF: A glial cell line derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130–1132.
57.
Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM Jr, Milbrandt J: Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996;384:467–470.
58.
Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, Lampe PA, Heuckeroth RO, Kotzbauer PT, Simburger KS, Golden JP, Davies JA, Vejsada R, Kato AC, Hynes M, Sherman D, Nishimura M, Wang LC, Vandlen R, Moffat B, Klein RD, Poulsen K, Gray C, Garces A, Henderson CE, Phillips HS, Johnson EM Jr: Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 1998;20:245–253.
59.
Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA and the NGF Study Group: Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998;51:695–702.
60.
Rask C, Sanders C, Häussler J: Positive results of phase I recombinant human nerve growth factor (rhNGF) triggers two phase III trials to confirm efficacy and safety in diabetic neuropathy. J Neurol 1998;245:447.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.